Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05338034
PHASE2

Phase 2a Study of HPG1860 in Subjects With NASH

Sponsor: Hepagene (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.

Official title: A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

89

Start Date

2021-11-22

Completion Date

2023-03-28

Last Updated

2026-05-28

Healthy Volunteers

No

Interventions

DRUG

HPG1860

The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.

DRUG

Placebo

Capsule

Locations (1)

South Texas Research Institute (STRI)

Texas City, Texas, United States